Digital Pathology AI
T

Tribun Health

Tribun Health sells CaloPix, software that pathology laboratories use to manage cases and review scanned slides on screen. Hospital and private laboratories, health systems and research groups use it to read, store and share slides, and it connects to the laboratory information system, scanners and storage.

CaloPix was FDA cleared in 2025 and is CE marked in Europe. Other companies' AI tools plug into it, from Mindpeak, Deep Bio, Owkin and Ibex, and each is covered on its maker's own record. Tribun's own AI includes QC4AI, which spots defects in scanned slides, and three breast cancer algorithms at version 1.0 for Ki67, ER and PR scoring, HER2 scoring and mitosis counting; the site gives agreement figures against pathologists for those three and states no regulatory status for any Tribun algorithm. Tribun also sells slide storage, remote consultation and imaging of surgical specimens, plus implementation, training and maintenance.

Tribun is a Paris company founded in 2006 as TRIBVN, with an office in Montreal. It reports more than 100 customers in Europe and North America, including the Paris hospital group AP-HP, and was named Best in KLAS for digital pathology in Europe from 2022 to 2024. It bought the French AI company Keen Eye in 2022 and holds ISO/IEC 27001 certification. No price is published.

AI Health Index verifiedNovember 8, 2026
Compare Tribun Health with other vendors
Founded
2006
Headquarters
Paris, France
Categories
pathology-ai
Indexed Products
CaloPix, CaloPix Connect, CaloPix Archive, TeleSlide Patho, MacroCam, QC4AI, Ki67-ER-PR by Tribun, HER2 by Tribun, Mitosis by Tribun
Buyer Segments
Hospital pathology laboratories, Health systems, Private diagnostic laboratories, Biopharma and contract research organizations
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
CC on AI CentralityArtificial intelligence is a feature layer on a product whose value stands without it. A learned component is a model whose parameters are estimated from data: machine learning, or a statistical model fitted to population data, including one then updated on the patient measurements. A fixed formula, a rule set, or a feedback controller that adjusts a dosing factor from the patient own readings is not one, however patient specific its output and whatever the vendor calls the adjustment.
Vendor Published

CaloPix is an image management platform, and the AI sits on top of it. Case management, slide review, archiving and remote consultation all work without any model, and most of the AI the platform carries comes from other manufacturers through CaloPix Connect.

Tribun's own AI is small beside the platform. Its AI catalog lists QC4AI, which recognizes and quantifies visual defects in scanned slides. Separate product pages on the site describe three more Tribun algorithms for breast cancer, each at version 1.0: Ki67-ER-PR, which scores cell positivity for the three biomarkers; HER2, which scores HER2 including low expressing cases; and Mitosis, which counts mitotic figures. The catalog does not list those three, and the company also offers custom algorithms built to a customer's request.

CC on Autonomy and Oversight ModelAutonomy is claimed and oversight is asserted without a mechanism. Human in the loop appears as a phrase rather than a described control.
Vendor Published

Review by laboratory staff is implied, but no control is described. QC4AI flags and measures visual defects in scanned slides inside the platform, where laboratory staff and pathologists decide whether to rescan. AI applications from other makers show their results to the pathologist in CaloPix.

Nothing published states the defect level at which QC4AI flags a slide, whether a flagged slide is held back from AI analysis or diagnosis, or what happens when a defect is missed.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

Tribun names its own algorithms and their versions, and describes the training data for one of them. The product pages for Ki67-ER-PR, HER2 and Mitosis each give version 1.0 and say what the model does: it separates tumor from normal cells and then scores the biomarker or counts mitotic figures. The Mitosis page says it was trained on more than 60,000 annotated mitotic figures from eight different scanners. QC4AI is described by function only. The outside applications in the catalog are named with their makers (Mindpeak, Deep Bio, Owkin and Ibex), so a buyer can see who builds each model.

No model type, update practice or release history is published for any Tribun algorithm, and nothing says when a version changes.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

Tribun builds QC4AI itself and names the maker of every hosted model. The outside models on the platform are listed with their manufacturers, Mindpeak, Deep Bio, Owkin and Ibex, so a buyer can see who supplies each AI result.

What is not published is the hosting provider, whether partner applications run inside CaloPix or send images to the partner's own systems, and any subprocessor list.

CC on Clinical and Operational EvidenceNamed customers, or vendor reported percentages with no method, denominator or reference standard. Scale of use is recorded here and is not treated as evidence of benefit.
Vendor Published

The platform has scale and outside recognition behind it, and Tribun's own AI has vendor figures only. The company reports more than 100 customers in Europe and North America, was named Best in KLAS for digital pathology in Europe in 2022, 2023 and 2024, and received FDA 510(k) clearance for CaloPix in May 2025. A customer testimonial from AP-HP, the Paris hospital group, describes using Owkin's RlapsRisk BC on CaloPix.

For its breast algorithms Tribun reports agreement with pathologists (F1 of 0.9 for Ki67, ER and PR; 0.82 for HER2; a Pearson correlation of 0.97 for mitotic density), with no study, method, denominator or test site published. No performance figure is published for QC4AI.

Named customers and vendor figures without method.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

Security controls are described; the questions the AI raises are not answered. Tribun lists database encryption, role based access, audit functions, password policies and a zero trust approach, and holds ISO/IEC 27001 certification.

Nothing published says how long slide images and case data are kept, whether customer slides train QC4AI or other models, or how any training data was de identified. No safety engineering for QC4AI is published.

Regulatory and Compliance
DD on HIPAA and BAA PostureNo statement of status and no privacy document that reaches the product. Both halves are absent at this grade: a service level privacy document on its own lifts a vendor to the band above even where no status is stated. A website privacy notice, including one that says it does not cover customer data, does not reach the product, so a vendor whose only document is that notice and who states no status grades here.
Vendor Published

Tribun states no HIPAA position, and no privacy document covers the product. The legal notice of Tribun Health SAS, written under the GDPR and French law, covers the website and information sent by email. It names a data protection officer and says no personal data is transferred outside the EU.

It does not address patient slide images or case data held in CaloPix. Nothing published states a HIPAA position or offers a business associate or data processing agreement, although CaloPix is FDA cleared and sold in North America.

BB on Security Certifications and Trust CenterA recognized certification is named in the vendor own material without the artifact, or with a scope or renewal question the buyer has to raise. A recognized certification here is an audit of how the vendor operates security, such as SOC 2, HITRUST or ISO/IEC 27001. A certification has a scope and a clock, and both are part of this grade. A certification the vendor attaches to its data center, hosting facility or cloud provider, rather than presenting as its own, is the host's and does not count here.
Vendor Published

The company names a recognized certification, without publishing it. It states that it is certified to ISO/IEC 27001, dated 2025, and describes encryption, role based access control, audit functions and a zero trust approach.

The certificate, its scope and its issuing body are not published. There is no trust center, SOC 2 report or penetration testing statement.

CC on FDA and Regulatory StatusNo device claim is made and the product is scoped accordingly. Most administrative and operational products sit here and are not penalized for it, because this axis grades the appropriateness of the positioning rather than possession of a clearance. A stated limit on use, such as research use only or a clause that the product gives no medical advice, beside marketing that sells the product for clinical decisions also sits here, with both quoted, because the buyer has to ask which one governs.
Regulatory Filing

The platform is cleared, and nothing is stated about the regulatory status of Tribun's own AI. CaloPix received FDA 510(k) clearance on 14 May 2025 (K250414, product code QKQ for whole slide imaging systems). It is also CE marked under the IVDR and licensed by Health Canada, and Tribun notes that status varies by version and configuration.

Tribun's AI catalog says each application carries its own manufacturer, intended use and regulatory status, and it lists QC4AI without either. The product pages for Ki67-ER-PR, HER2 and Mitosis call each a software based in vitro medical device that supports pathologists in diagnosing or scoring breast cancer, and none states a CE marking, an FDA status or a research use label. A platform clearance covers the image management and viewing functions, not an AI application running on them.

CC on AI Governance and Bias DisclosureResponsible artificial intelligence is committed to in policy language with no evaluation behind it. Most of the index sits here.
Vendor Published

Tribun publishes test results for its algorithms, and nothing on how they are governed. The product pages compare each breast algorithm with pathologists: an F1 score of 0.9 for Ki67, ER and PR, an average F1 of 0.82 for HER2, and a Pearson correlation of 0.97 for mitotic density. The Mitosis page adds that its training data came from eight scanners, the condition that most often moves results in pathology.

No result is broken down by scanner, stain, laboratory or patient group, no study or method is published behind the figures, and QC4AI carries no evaluation at all. No governance framework, responsible AI policy or post release monitoring is described. For the outside applications it hosts, the catalog notes only that each has its own manufacturer and regulatory status.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

Staff and pathologists can check the outputs, and nothing stands behind them. CaloPix has audit functions, QC4AI's defect flags are shown to staff who decide whether to rescan, and the breast algorithms' pages describe a pathologist reviewing the analysis results before using them.

The agreement figures on those pages (F1 scores against pathologists) come with no method, denominator or test set, so they are not an error rate a buyer can hold the company to. No warranty, remedy or correction route is published for any Tribun algorithm. Responsibility for the outside applications sits with their manufacturers.

Integration and Deployment
CC on EHR and Interoperability DepthIntegration is claimed through standards or a middleware layer with no system named and nothing to verify.
Vendor Published

Connection to the laboratory system is claimed, without any system named. CaloPix is itself the laboratory's image and case system, and the home page says it connects with laboratory information systems, scanners, storage and AI applications, associating images with case data from the LIS. Tribun sells interoperability as an implementation service, publishes an article on DICOM for digital pathology, and offers CaloPix Connect as an open API that brings AI applications into the workflow.

No laboratory information system, record system or production interface is named, and no integration documentation is published.

CC on Deployment Model and Data ResidencyA single hosted option with location implied rather than committed.
Vendor Published

CaloPix is web based, and where it runs is implied, not stated. CaloPix Archive manages slide images across hot, cold and long term storage. Tribun's legal notice says it transfers no personal data outside the EU, but that statement covers website and email data.

Nothing published says where customer slide images are hosted, whether CaloPix can run on premises, or where North American customers' data rests.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

No price is published, but what a laboratory buys can be worked out. Tribun sells CaloPix with archive, remote consultation and specimen imaging modules, and outside AI applications through its catalog. It also sells consulting, implementation, interoperability, training and maintenance services.

No license basis, per slide or per user price, or implementation fee is published.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

Tribun names who CaloPix serves, with a clearance behind the platform. CaloPix serves hospital and private diagnostic laboratories, health systems, research centers, drug companies and contract research organizations, for whole slide review in routine diagnosis and research. Its May 2025 FDA clearance (K250414) and IVDR marking cover the platform within the scope each states.

QC4AI applies to H&E and other scanned slides for quality control, with no validation published.

Alternatives

Alternatives to Tribun Health

Other products that do the same kind of work as Tribun Health, and what each one does.

All Tribun Health alternatives, with prices →

PathAI sells AISight, a cloud image management system that anatomic pathology laboratories use to manage cases, read slides on screen and run AI, along with its own algorithms and a menu of partner algorithms.

Deep Bio builds deep learning algorithms for cancer pathology, led by prostate.

Aiosyn sells AI that analyzes images of stained tissue, to pathology laboratories and to drug companies running animal studies.

aetherAI sells aetherSlide, a system hospital pathology departments use to manage and review scanned slides, along with its own AI for bone marrow smears and colonoscopy. aetherSlide holds FDA clearance (K233126, 2024), Taiwan approval and CE marking, and is named at hospitals in Taiwan…

Gestalt sells PathFlow, a digital pathology platform that private laboratories, health networks and academic centers use to bring slides, case and patient information and AI results into one workspace.

Biomy makes DeepPathFinder, cloud software that uses AI to map immune and cancer cells on tissue slides for drug research.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published
Image management platform (CaloPix) with archive, remote consultation and gross imaging modules, plus implementation, interoperability, training and maintenance services; third party AI applications through the catalog. No license basis or price published. Not published. The legal notice covers the website under the GDPR; no data processing or business associate agreement is published. Implementation and interoperability are sold as services; fees not published. Vendor Published

Tribun describes the platform modules and services a laboratory buys, without a license basis, per slide or per user price, storage price or implementation fee. Third party AI applications carry their own manufacturers' terms, and custom algorithms are offered on request. The CaloPix license basis, archive pricing by volume and the cost of each AI application through the platform are not published.

Tribun Health pricing in full →